tetano
Editor, Senior Moderator
Hematol Transfus Cell Ther
. 2022 Jan 19.
doi: 10.1016/j.htct.2021.11.015. Online ahead of print.
Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature
Bruno Almeida Costa[SUP] 1 2 [/SUP], Kaiza Vilarinho da Luz[SUP] 3 [/SUP], Sarah Emanuelle Viana Campos[SUP] 1 [/SUP], Germison Silva Lopes[SUP] 1 4 [/SUP], João Paulo de Vasconcelos Leitão[SUP] 1 [/SUP], Fernando Barroso Duarte[SUP] 1 5 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) may present with extrapulmonary manifestations, including hematologic changes. Previous studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) can interact with the renin-angiotensin system, ultimately causing increased production of angiotensin II. By reporting the cases of previously healthy young adults diagnosed with a hematologic malignancy after experiencing COVID-19, we raise the hypothesis that the SARS-Cov-2 infection could act as a trigger for leukemogenesis in predisposed individuals.
Methods: This was a case series performed through extraction of relevant clinical information from the medical records of three patients admitted to our Hematology unit between August 2020 and September 2020.
Main results: Considering the relatively rapid development of cytopenias following recovery from COVID-19, it cannot be ruled out that SARS-Cov-2 played a role in leukemogenesis in those patients. Based on previous in vitro studies, the renin-angiotensin system imbalance induced by SARS-CoV-2 could potentially promote in vivo leukemogenesis through several mechanisms.
Conclusion: Despite the advances in pathophysiological and clinical characterization of COVID-19, the consequences of the pandemic to the incidence of hematologic diseases are still to be elucidated. In this context, future dissection of the status of the local bone marrow renin-angiotensin system in leukemogenesis is a clinically relevant basic research area.
Keywords: Acute leukemia; COVID-19; Hematologic malignancy; Renin-angiotensin system; SARS-CoV-2.
. 2022 Jan 19.
doi: 10.1016/j.htct.2021.11.015. Online ahead of print.
Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature
Bruno Almeida Costa[SUP] 1 2 [/SUP], Kaiza Vilarinho da Luz[SUP] 3 [/SUP], Sarah Emanuelle Viana Campos[SUP] 1 [/SUP], Germison Silva Lopes[SUP] 1 4 [/SUP], João Paulo de Vasconcelos Leitão[SUP] 1 [/SUP], Fernando Barroso Duarte[SUP] 1 5 [/SUP]
Affiliations
- PMID: 35075445
- PMCID: PMC8768508
- DOI: 10.1016/j.htct.2021.11.015
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) may present with extrapulmonary manifestations, including hematologic changes. Previous studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) can interact with the renin-angiotensin system, ultimately causing increased production of angiotensin II. By reporting the cases of previously healthy young adults diagnosed with a hematologic malignancy after experiencing COVID-19, we raise the hypothesis that the SARS-Cov-2 infection could act as a trigger for leukemogenesis in predisposed individuals.
Methods: This was a case series performed through extraction of relevant clinical information from the medical records of three patients admitted to our Hematology unit between August 2020 and September 2020.
Main results: Considering the relatively rapid development of cytopenias following recovery from COVID-19, it cannot be ruled out that SARS-Cov-2 played a role in leukemogenesis in those patients. Based on previous in vitro studies, the renin-angiotensin system imbalance induced by SARS-CoV-2 could potentially promote in vivo leukemogenesis through several mechanisms.
Conclusion: Despite the advances in pathophysiological and clinical characterization of COVID-19, the consequences of the pandemic to the incidence of hematologic diseases are still to be elucidated. In this context, future dissection of the status of the local bone marrow renin-angiotensin system in leukemogenesis is a clinically relevant basic research area.
Keywords: Acute leukemia; COVID-19; Hematologic malignancy; Renin-angiotensin system; SARS-CoV-2.